Researchers report safer rotavirus vaccine

Rotavirus kills millions of children in developing countries each year Copyright: Bernard Osès/IRD

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:

You have to credit our authors.
You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
The easiest way to get the article on your site is to embed the code below.

For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

<div class="article-wrap">
<div id="article-introduction">
<h1>Researchers report safer rotavirus vaccine</h1>
<h4></h4>
</div>
<br />
<br />

<div id="article-body">
<p><P>Harmful side effects of vaccination against rotavirus — which kills millions of children worldwide, mainly in developing countries — could be avoided with a new vaccine, say researchers. Unlike the previous vaccine, it does not create an increased risk of bowel blockage, a problem that led to its predecessor’s withdrawal in the United States.</P><br />
<P>The findings were presented on 31 October at a meeting of the American Society for Microbiology. The vaccine, made by GlaxoSmithKline Biologicals, was tested in more than 63,000 infants in Latin America and Finland. Children who were vaccinated and those who received a placebo vaccine developed bowel blockages in equal proportions. </P><br />
<P>The new vaccine, known as Rotarix, has been licensed for use in Mexico. GlaxoSmithKline Biologicals aims to obtain licenses for its use in the rest of Latin America, Asia, and Europe. The company also intends to start trials in the United States. </P><br />
<P></P><br />
<P><a  href="http://www.denverpost.com/Stories/0,1413,36~11676~2504990,00.html" target="_blank" onclick="pageTracker._trackPageview('/tracking/external/'+this.href);" rel="noopener noreferrer">Link to full DenverPost.com news story</A> </P></p>

</div>
<div class="quick-links-wrapper">
<h3>You might also like</h3>
[related-articles]
</div>
<p>This article was originally published on <a href="https://www.scidev.net" target="_blank">SciDev.Net</a>. Read the <a href="https://www.scidev.net/global/news/researchers-report-safer-rotavirus-vaccine/" target="_blank">original article</a>.</p>
<script type="text/javascript">
(function(e,t,n,r,i,s,o){e["GoogleAnalyticsObject"]=i;e[i]=e[i]||function(){(e[i].q=e[i].q||[]).push(arguments)},e[i].l=1*new Date;s=t.createElement(n),o=t.getElementsByTagName(n)[0];s.async=1;s.src=r;o.parentNode.insertBefore(s,o)})(window,document,"script","//www.google-analytics.com/ga.js","ga");var _gaq=_gaq||[];var _gaq=_gaq||[];_gaq.push(["_setAccount","UA-3223906-8"],["_trackEvent","article interaction","republished","https://www.scidev.net/global/news/researchers-report-safer-rotavirus-vaccine/",null,true])
</script>
</div>

Harmful side effects of vaccination against rotavirus — which kills millions of children worldwide, mainly in developing countries — could be avoided with a new vaccine, say researchers. Unlike the previous vaccine, it does not create an increased risk of bowel blockage, a problem that led to its predecessor’s withdrawal in the United States.

The findings were presented on 31 October at a meeting of the American Society for Microbiology. The vaccine, made by GlaxoSmithKline Biologicals, was tested in more than 63,000 infants in Latin America and Finland. Children who were vaccinated and those who received a placebo vaccine developed bowel blockages in equal proportions.

The new vaccine, known as Rotarix, has been licensed for use in Mexico. GlaxoSmithKline Biologicals aims to obtain licenses for its use in the rest of Latin America, Asia, and Europe. The company also intends to start trials in the United States.

Link to full DenverPost.com news story